Clinical Trials Directory

Trials / Terminated

TerminatedNCT03180853

Multiple Myeloma Patient Registry

Status
Terminated
Phase
Study type
Observational
Enrollment
85 (actual)
Sponsor
Janssen Scientific Affairs, LLC · Industry
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

The purpose of this study is to document the participants characteristics, disease burden, and clinical management of participants in the United States who are treated for relapsed multiple myeloma in routine medical practice with a treatment strategies that include a proteasome inhibitor (PI) and/or immunomodulatory drug (IMiD) used either as monotherapy or combination therapy with other treatments.

Conditions

Timeline

Start date
2017-05-08
Primary completion
2018-04-06
Completion
2018-04-06
First posted
2017-06-08
Last updated
2025-02-03

Locations

69 sites across 1 country: United States

Source: ClinicalTrials.gov record NCT03180853. Inclusion in this directory is not an endorsement.